Company / SG&A Expense
TENAX THERAPEUTICS, INC. SG&A Expense History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.8M
FY2025
5-year range
$3.7M / $13.8M
FY2021-FY2025
Trend
+35.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $14M to $7M over the past 9 years.
Based on SEC 10-K filings.
$7M in FY2025 with a 10-year CAGR of -6.8%.
Improved from $14M to $7M over the past 9 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -6.8%
Key checks
Key Insights
- In FY2025, sg&a expense increased 35.6% year-over-year.
- Peak sg&a expense was recorded in FY2016.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.8M | +35.6% |
| FY2024 | $5.0M | -63.7% |
| FY2016 | $13.8M | +0.0% |
| FY2015 | $13.8M | +274.7% |
| FY2014 | $3.7M | -39.7% |
| FY2013 | $6.1M | -20.7% |
| FY2012 | $7.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026